Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report first quarter 2014 financial and operating results and provide an update on May 19, 2014. The update will include its collaboration with Intrexon Corporation (NYSE:XON). David Pernock, chairman and chief executive officer of Fibrocell Science, will host the conference call and webcast at 5 p.m. EDT, May 19, 2014.
Help employers find you! Check out all the jobs and post your resume.
